DenialHelpUnderstand your atopic dermatitis (ad / eczema) denial. Build a reviewable appeal.
Upload the denial notice, verify the extracted facts, identify missing evidence, and prepare a package for treating-clinician review. The notice and applicable rules determine the available route and deadline.
Start my appeal→
See how it worksThe denial notice
Confirm the payer's stated reason, plan language, dates, and review rights from the actual notice.
Facts and evidence
Keep extracted information linked to its source. Unknown facts stay unknown until you or the clinician confirms them.
Route and review
Classify the next step, verify any deadline, and identify what requires treating-clinician review or signature.
Four clear stages.
Upload your denial — and any clinical records you have
Take a photo, scan, or upload PDFs of the denial letter. Adding labs, prior PA letters, or visit notes makes the appeal stronger — but the denial alone is enough to start.
Confirm a few facts
We pre-fill what was extracted. You confirm, correct, or leave it unknown.
We draft your appeal
A source-linked draft and evidence checklist for treating-clinician review.
Your doctor signs and files
We email the letter to you. Your doctor reviews, signs, and submits.
Common questions
Can I appeal a denied insurance claim for Atopic dermatitis (AD / eczema)?
The denial notice and governing plan or program determine whether and how the decision can be challenged. DenialHelp first classifies the route, then organizes the relevant facts and sources. Filing dates vary and must be verified against the actual notice.
What does DenialHelp cost for a Atopic dermatitis (AD / eczema) appeal?
$39 for a first-level appeal. Other review levels use the current prices shown on the pricing page. The refund promise concerns the described deliverable, not the insurer's decision.
Who reviews and signs the Atopic dermatitis (AD / eczema) appeal letter?
The patient's treating physician reviews and signs the appeal letter before it is submitted to the insurer. DenialHelp drafts the letter; the patient and prescribing physician are responsible for submission. We do not file appeals on behalf of patients.
What treatments are covered under Atopic dermatitis (AD / eczema)?
Dupixent (dupilumab) SC — IL-4Rα blocker (FDA Mar 2017 adult, Mar 2019 ages 12-17, May 2020 ages 6-11, Jun 2022 ages 6mo-5yr), Adbry (tralokinumab) 300 mg SC q2wk — IL-13 specific (FDA Dec 2021 adult, Dec 2023 ages 12+), Ebglyss (lebrikizumab) SC — IL-13 high-affinity (FDA Sep 2024 ages 12+ and >=40 kg), Nemluvio (nemolizumab) SC — IL-31Rα blocker (FDA Aug 2024 prurigo nodularis, Dec 2024 AD ages 12+), Cibinqo (abrocitinib) 100/200 mg PO daily — JAK1 inhibitor (FDA Jan 2022 adult, Feb 2023 ages 12+), Rinvoq (upadacitinib) 15/30 mg PO daily — JAK1 inhibitor (FDA Jan 2022 adult AD, Apr 2022 ages 12+), Opzelura (ruxolitinib 1.5%) topical cream — JAK1/2 (FDA Sep 2021 AD ages 12+ short-term/non-continuous), Eucrisa (crisaborole 2%) topical PDE-4 ointment — FDA Dec 2016 ages 3 mo+
Ready to fight your denial?
Our free pre-payment review runs before checkout. Refund requests made within 7 calendar days of payment are processed automatically; later requests are reviewed under the Terms. A refund policy is not a promise of a payer outcome.
Start my appeal→